HIV molecular immunology database
Found 1 matching record:
HXB2 Location | Gag(77-85) | Gag Epitope Map
View variants at this location |
||||
---|---|---|---|---|---|---|
Epitope |
SLYNTVATL
|
Epitope Alignment | ||||
Variants |
|
|||||
Epitope Name | SL9 | |||||
Species (MHC/HLA) | human, transgenic mouse(A2) |
Showing 1 of 4 variants.
Variant ID. | 78 |
---|---|
Epitope Seq. | SLYNTVATL |
Variant Seq. | SLfNlVATL |
Mutations | Y/F T/L |
Epitope Location | Y3F T5L |
HXB2 Location | Y79F T81L |
Mutation Type | SF: susceptible form |
Method | CD8 T-cell Elispot - IFNy, Chromium-release assay |
Note | To identify immunogenically optimized epitopes for use in vaccines, mutants of SL9 were tested in transgenic mice. SLYNTVATL and most common mutant, SLfNTVATL, were weakly immunogenic or cross-reactive. 3 mutants, SLYNlVATL, SLfNlVATL and SiYNlVATL were highly immunogenic. Peptide SiYNlVATL with the additional L2I change allowed great cross-reactivity to the consensus. |
Blondelle2008 Sylvie E. Blondelle, Rosa Moya-Castro, Keiko Osawa, Kim Schroder, and Darcy B. Wilson. Immunogenically Optimized Peptides Derived from Natural Mutants of HIV CTL Epitopes and Peptide Combinatorial Libraries. Biopolymers, 90(5):683-694, 2008. PubMed ID: 18481808. Show all entries for this paper.